WHAT IS CLAIMED IS:

1. A medicinal preparation containing phenylethanoid glycosides extracted from *Cistance tubulosa (Schenk.) Wight*, said preparation comprising 10-70% of echinacoside by weight of said preparation, and 1-40% of acteoside by weight of said preparation.

2. The preparation as defined in claim 1 comprising 25-70% of echinacoside by weight of said preparation, and 5-40% of acteoside by weight of said preparation.

3. The preparation as defined in claim 1 which is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight*.

4. The preparation as defined in claim 1 further comprising 2'-acetylacteoside; campneoside I; campneoside II; cistantubuloside A, B_1, B_2, C_1, C_2; crenatoside; decaffeoylacteoside; isoacteoside; rhodioloside; syringalide A; 3'-α-L-rhamnopyranoside, and tubuloside A, each being contained in an amount less than 5% by weight of said preparation.

5. A process for making a medicinal preparation containing phenylethanoid glycosides, said process comprising the following steps of:

a) extracting subterranean portions of *Cistanche tubulosa (Schenk.) Wight* with a first polar solvent;

b) introducing the resulting extract from step a) into a column which is packed with hydrophobic macro-porous polymeric beads, thereby enabling phenylethanoid glycosides to be adsorbed on the polymeric beads;

c) eluting the column by use of a second polar solvent serving as a mobile phase, so that relatively less strongly adsorbed compounds are eluted from the column with most of phenylethanoid glycosides still being adsorbed on the polymeric beads; and

d) eluting the column by use of a third polar solvent so as to obtain an eluate which contains phenylethanoid glycosides, wherein the third polar solvent is lower in polarity than the second polar solvent.

6. The process as defined in claim 5, wherein the subterranean portions of *Cistanche tubulosa (Schenk.) Wight* in step a) are fleshy stems.

7. The process as defined in claim 5, wherein said extracting in step a) comprises mixing the subterranean portions of *Cistanche tubulosa (Schenk.) Wight* with the first polar solvent, decocting the resulting mixture for 0.5-10 hours, and filtering the decocted mixture to obtain a liquid extract or concentrating the liquid in vacuo to obtain an extract in the concentrated form.

8. The process as defined in claim 7, wherein the first polar solvent is water, or a mixture of water and ethanol.

9. The process as defined in claim 5, wherein the polymeric beads in step b) are cross-linked polyaromatics.

10. The process as defined in claim 9, wherein the polymeric beads are formed of cross-linked polystyrene or cross-linked copolymer of styrene and divinyl benzene.

11. The process as defined in claim 5, wherein the second polar solvent is water; wherein the third polar solvent is methanol, ethanol, a mixture of water and methanol, or a mixture of water and ethanol.

12. The process as defined in claim 11, wherein the third polar solvent is the mixture of water and ethanol.

13. The process as defined in claim 5 further comprising removing a solvent that is contained in the eluate from step d), thereby resulting in production of a dry preparation.

14. A medicinal composition for use in the prevention of senile dementia, said medicinal composition comprising a therapeutically effective amount of the preparation as claimed in any one of claims 1 to 4 as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient.

15. A medicinal composition for use in the inhibition of aggregation of blood platelets, said medicinal composition comprising a therapeutically effective amount of the preparation as claimed in any one of claims 1 to 4 as an active ingredient, in admixture with a pharmaceutically acceptable carrier or diluent for the active ingredient.

16. A method of treating and preventing an individual suffering senile dementia comprising administering to the individual a therapeutically effective amount of the preparation as claimed in claim 1.

17. A method of inhibiting blood platelets aggregation in an individual comprising administering to the individual a therapeutically effective amount of the preparation as claimed in claim 1.

18. The method as defined in claim 14, wherein the preparation comprises 25-70% of echinacoside by weight of said preparation, and 5-40% of acteoside by weight of said preparation.

19. The method as defined in claim 14, wherein the preparation is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight.*

20. The method as defined in claim 15, wherein the preparation comprises 25-70% of echinacoside by weight of said preparation, and 5-40% of acteoside by weight of said preparation.

21. The method as defined in claim 15, wherein the preparation is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight.*

22. The method as defined in claim 16, wherein the preparation comprises 25-70% of echinacoside by weight of said preparation, and 5-40% of acteoside by weight of said preparation.

23. The method as defined in claim 16, wherein the preparation is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight*.

24. The method as defined in claim 17, wherein the preparation comprises 25-70% of echinacoside by weight of said preparation, and 5-40% of acteoside by weight of said preparation.

25. The method as defined in claim 17, wherein the preparation is extracted from fleshy stems of *Cistance tubulosa (Schenk.) Wight*.